KR20240093725A - 알부민 융합 단백질의 정제 방법 - Google Patents
알부민 융합 단백질의 정제 방법 Download PDFInfo
- Publication number
- KR20240093725A KR20240093725A KR1020247016329A KR20247016329A KR20240093725A KR 20240093725 A KR20240093725 A KR 20240093725A KR 1020247016329 A KR1020247016329 A KR 1020247016329A KR 20247016329 A KR20247016329 A KR 20247016329A KR 20240093725 A KR20240093725 A KR 20240093725A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- sequence
- cd40l
- loop
- scaffold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562132198P | 2015-03-12 | 2015-03-12 | |
| US62/132,198 | 2015-03-12 | ||
| PCT/US2016/022003 WO2016145307A1 (en) | 2015-03-12 | 2016-03-11 | Method of purifying albumin-fusion proteins |
| KR1020177028780A KR20170124592A (ko) | 2015-03-12 | 2016-03-11 | 알부민 융합 단백질의 정제 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177028780A Division KR20170124592A (ko) | 2015-03-12 | 2016-03-11 | 알부민 융합 단백질의 정제 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240093725A true KR20240093725A (ko) | 2024-06-24 |
Family
ID=56878920
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247016329A Pending KR20240093725A (ko) | 2015-03-12 | 2016-03-11 | 알부민 융합 단백질의 정제 방법 |
| KR1020177028780A Ceased KR20170124592A (ko) | 2015-03-12 | 2016-03-11 | 알부민 융합 단백질의 정제 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177028780A Ceased KR20170124592A (ko) | 2015-03-12 | 2016-03-11 | 알부민 융합 단백질의 정제 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10683340B2 (enExample) |
| EP (2) | EP3842451A1 (enExample) |
| JP (3) | JP6862348B2 (enExample) |
| KR (2) | KR20240093725A (enExample) |
| CN (1) | CN107428817B (enExample) |
| AU (3) | AU2016228806B2 (enExample) |
| CA (1) | CA2977675A1 (enExample) |
| ES (1) | ES2839211T3 (enExample) |
| IL (1) | IL253971B (enExample) |
| WO (1) | WO2016145307A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2851667A1 (en) | 2011-10-11 | 2013-04-18 | Medimmune, Llc | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| SG11202003793WA (en) | 2017-10-30 | 2020-05-28 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| IL278710B2 (en) | 2018-05-16 | 2025-09-01 | Lib Therapeutics Llc | Compositions comprising pcsk9 binding compounds and methods of use |
| CA3117875A1 (en) * | 2018-11-09 | 2020-05-14 | Neopep Pharma Gmbh & Co. Kg | Polypeptides for the treatment of stress, immunoreaction and stroke syndromes |
| EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| CN110295152A (zh) * | 2019-07-29 | 2019-10-01 | 北京泓恩生物科技有限公司 | 一种重组产朊假丝酵母尿酸酶的纯化方法 |
| US11186625B2 (en) * | 2019-12-06 | 2021-11-30 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CN115996940A (zh) * | 2020-07-01 | 2023-04-21 | 免疫医疗有限责任公司 | 用于纯化生物治疗剂的洗涤剂和方法 |
| CN112062833A (zh) * | 2020-10-09 | 2020-12-11 | 国药集团武汉血液制品有限公司 | 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法 |
| CN115677848A (zh) * | 2022-10-24 | 2023-02-03 | 通化安睿特生物制药股份有限公司 | 一种制备高纯度高稳定性蛋白质的方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| JP4251406B2 (ja) | 1990-04-05 | 2009-04-08 | クレア，ロベルト | ウォーク―スルー突然変異誘発 |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| NZ511699A (en) | 1998-12-02 | 2003-02-28 | Phylos Inc | DNA-protein fusions and uses thereof |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2377468C (en) | 1999-07-27 | 2010-04-20 | Phylos, Inc. | Peptide acceptor ligation methods |
| US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
| AU2002310502A1 (en) | 2001-06-21 | 2003-01-08 | Phylos, Inc. | In vitro protein interaction detection systems |
| KR100524872B1 (ko) | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| US9012369B2 (en) | 2004-07-06 | 2015-04-21 | Pfizer Inc. | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
| AU2006329215A1 (en) | 2005-12-22 | 2007-06-28 | Conjuchem Biotechnologies Inc. | Process for the production of preformed conjugates of albumin and a therapeutic agent |
| KR20150003908A (ko) | 2007-07-03 | 2015-01-09 | 다누타 크루셰프스카 | 유기 바이오연료의 제조를 위한 알파케토글루타레이트의 용도 |
| US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| CN101932720A (zh) | 2007-10-31 | 2010-12-29 | 米迪缪尼有限公司 | 蛋白质支架 |
| RS55218B1 (sr) | 2008-10-31 | 2017-02-28 | Janssen Biotech Inc | Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe |
| MX2011008566A (es) | 2009-02-12 | 2011-11-29 | Janssen Biotech Inc | Composiciones supercontigo basadas en el dominio de fibronectina tipo iii, metodos y usos. |
| EP2427486B1 (en) * | 2009-05-07 | 2015-02-25 | Novozymes Biopharma DK A/S | Method for purifying albumin |
| JP2013509170A (ja) | 2009-10-30 | 2013-03-14 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | アルブミン変異体 |
| ES2678144T3 (es) | 2010-02-16 | 2018-08-09 | Medimmune, Llc | Composiciones relacionadas con SAH y métodos de uso |
| JP2013523179A (ja) | 2010-04-13 | 2013-06-17 | メディミューン，エルエルシー | フィブロネクチンタイプｉｉｉドメインに基づく多量体足場 |
| JP2014510518A (ja) | 2011-02-15 | 2014-05-01 | メディミューン，エルエルシー | Ｈｓａ関連組成物および使用方法 |
| CA2851667A1 (en) * | 2011-10-11 | 2013-04-18 | Medimmune, Llc | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| RU2670063C2 (ru) * | 2012-11-08 | 2018-10-17 | Альбумедикс А/С | Варианты альбумина |
-
2016
- 2016-03-11 KR KR1020247016329A patent/KR20240093725A/ko active Pending
- 2016-03-11 WO PCT/US2016/022003 patent/WO2016145307A1/en not_active Ceased
- 2016-03-11 JP JP2017548053A patent/JP6862348B2/ja active Active
- 2016-03-11 EP EP20198757.5A patent/EP3842451A1/en active Pending
- 2016-03-11 CA CA2977675A patent/CA2977675A1/en active Pending
- 2016-03-11 CN CN201680014597.2A patent/CN107428817B/zh active Active
- 2016-03-11 US US15/557,358 patent/US10683340B2/en active Active
- 2016-03-11 ES ES16762595T patent/ES2839211T3/es active Active
- 2016-03-11 EP EP16762595.3A patent/EP3268389B1/en active Active
- 2016-03-11 AU AU2016228806A patent/AU2016228806B2/en active Active
- 2016-03-11 KR KR1020177028780A patent/KR20170124592A/ko not_active Ceased
-
2017
- 2017-08-14 IL IL253971A patent/IL253971B/en unknown
-
2020
- 2020-06-15 US US16/901,812 patent/US11548933B2/en active Active
-
2021
- 2021-01-22 AU AU2021200423A patent/AU2021200423B2/en active Active
- 2021-03-31 JP JP2021061713A patent/JP7320550B2/ja active Active
-
2023
- 2023-01-06 US US18/150,983 patent/US20230340074A1/en active Pending
- 2023-05-16 JP JP2023080507A patent/JP2023103368A/ja active Pending
- 2023-07-03 AU AU2023204271A patent/AU2023204271A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016228806B2 (en) | 2020-10-22 |
| CA2977675A1 (en) | 2016-09-15 |
| AU2016228806A1 (en) | 2017-08-31 |
| KR20170124592A (ko) | 2017-11-10 |
| US20230340074A1 (en) | 2023-10-26 |
| IL253971A0 (en) | 2017-10-31 |
| US10683340B2 (en) | 2020-06-16 |
| JP2021105025A (ja) | 2021-07-26 |
| CN107428817B (zh) | 2022-07-12 |
| IL253971B (en) | 2021-10-31 |
| EP3268389A4 (en) | 2018-08-08 |
| AU2021200423B2 (en) | 2023-04-06 |
| WO2016145307A1 (en) | 2016-09-15 |
| JP6862348B2 (ja) | 2021-04-21 |
| ES2839211T3 (es) | 2021-07-05 |
| BR112017019401A2 (pt) | 2018-05-02 |
| US20200407423A1 (en) | 2020-12-31 |
| EP3268389B1 (en) | 2020-09-30 |
| EP3268389A1 (en) | 2018-01-17 |
| US11548933B2 (en) | 2023-01-10 |
| US20180105575A1 (en) | 2018-04-19 |
| CN107428817A (zh) | 2017-12-01 |
| EP3842451A1 (en) | 2021-06-30 |
| AU2021200423A1 (en) | 2021-02-25 |
| JP2023103368A (ja) | 2023-07-26 |
| AU2023204271A1 (en) | 2023-07-27 |
| JP2018513124A (ja) | 2018-05-24 |
| JP7320550B2 (ja) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021200423B2 (en) | Method of purifying albumin-fusion proteins | |
| JP7560507B2 (ja) | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 | |
| US20250197497A1 (en) | Methods for purifying heterodimeric, multispecific antibodies | |
| CA3059994C (en) | Human coagulation factor ix (fix) fusion protein, preparation method therefor, and use thereof | |
| EP3113858B1 (en) | Il-15/il-15ralpha based conjugates purification method | |
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| JPWO2020061478A5 (enExample) | ||
| KR20250148832A (ko) | 알부민 융합 단백질의 정제방법 | |
| HK1245286B (en) | Method of purifying albumin-fusion proteins | |
| BR112017019401B1 (pt) | Método de purificação de proteínas de fusão de albumina | |
| BR122024023456A2 (pt) | COMPOSIÇÃO COMPREENDENDO SUPORTES Tn3 | |
| RU2820588C2 (ru) | Способы очистки гетеродимерных полиспецифических антител | |
| RU2826189C2 (ru) | Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения | |
| HK40090436A (zh) | Cd40l-特异性tn3-衍生的支架及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |